CUE
CUE
NASDAQ · Biotechnology

Cue Biopharma Inc

$27.45
-3.96 (-12.61%)
As of Sep 28, 10:34 PM ET ·
Financial Highlights (FY 2026)
Revenue
63.96M
Net Income
-61,945,321
Gross Margin
—
Profit Margin
-96.9%
Rev Growth
+180.1%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — — 40.2% 40.2%
Operating Margin -96.7% -402.2% -10.0% -9.6%
Profit Margin -96.9% -416.1% -8.8% -9.5%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 63.96M 17.68M 17.52M 19.24M
Gross Profit — — 7.05M 7.74M
Operating Income -61,827,144 -71,104,630 -1,757,465 -1,843,438
Net Income -61,945,321 -69,679,191 -1,532,650 -1,824,826
Gross Margin — — 40.2% 40.2%
Operating Margin -96.7% -402.2% -10.0% -9.6%
Profit Margin -96.9% -416.1% -8.8% -9.5%
Rev Growth +180.1% -14.7% +0.6% +3.6%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 2.58M 12.69M 12.70M
Total Equity — 10.40M 8.33M 9.35M
D/E Ratio — 0.25 1.52 1.36
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -61,046,135 -74,344,734 -1,913,244 -2,419,019
Free Cash Flow — — -1,533,941 -1,392,757